-DNA India is expected to bear the brunt of $160 billion trade-distorting farm subsidies provided by developed nations like the US At a time when angry farmer protests seeking an increase in the Minimum Support Price (MSP) for all crops is on an upswing, India faces an uphill task to protect its food procurement operations at the forthcoming Buenos Aires Ministerial of the World Trade Organisation (WTO) from December 10-13. At...

-Press release from People's Budget Initiative (PBI)/ Centre for Budget and Governance Accountability (CBGA) New Delhi: The coalition -- People’s Budget Initiative (PBI) with a membership of diverse organisations working across different sectors in the country, organized a national convention on pressing issues (such as budgetary allocations for social sectors, transparency etc.) deserving a closer scrutiny and a larger public debate. The two-day workshop entitled ‘Civil Society Budget Work and Governance...

-Outlook India's neighbour, Pakistan, stands fourth in the list with 40 per cent bribery rate. If the statistics furnished by the transparency international (TI), an anti-corruption global civil society organisation, are anything to go by, India has a long way ahead to fulfil one of the many objectives as told by the current Indian government - defeating the malice of corruption. A recent survey by the transparency international states that India is the...

-TheWire.in The negotiator’s comments were non-committal but indicated that for now, the RCEP talks have not yet moved decisively into a TRIP-plus scenario. The chief negotiator for New Zealand, at the Asia trade pact talks in Hyderabad this week, made pointed reference to TRIPS-plus (Trade-Related Aspects of Intellectual Property Rights) provisions, saying that while the TRIPS agreement on intellectual property rights was sufficient, it was up to the countries to analyse whether...

-The Telegraph New Delhi: Regulatory efforts to get doctors in India to prescribe medicines only through their generic names, initiated about 15 years ago, will need to overcome legal challenges and resistance from sections of doctors and the pharmaceutical industry, experts said. Senior pharmacologists and industry analysts have also said it will be misleading to presume that prescriptions with generic names will automatically translate into lower medicine bills for patients as studies...